Why Is Progress in Acute Myeloid Leukemia So Slow?

Topp, 2015, Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study, Lancet Oncol, 16, 57, 10.1016/S1470-2045(14)71170-2 Lee, 2015, T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial, Lancet Oncol, 385, 517, 10.1016/S0140-6736(14)61403-3 Byrd, 2014, Entering the era of targeted therapy for chronic lymphocytic leukemia: impact on the practicing clinician, J Clin Oncol, 32, 3039, 10.1200/JCO.2014.55.8262 Cortes, 2013, A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias, N Engl J Med, 369, 1783, 10.1056/NEJMoa1306494 Lo-Coco, 2013, Retinoic acid and arsenic trioxide for acute promyelocytic leukemia, N Engl J Med, 369, 111, 10.1056/NEJMoa1300874 Othus, 2014, Declining rates of treatment-related mortality in patients with newly diagnosed acute myeloid leukemia (AML) given “intensive” induction regimens: a report from the Southwest Oncology Group (SWOG) and MD Anderson Cancer Center (MDA), Leukemia, 28, 289, 10.1038/leu.2013.176 Lancet, 2013, New agents: great expectations not realized, Best Pract Res Clin Haematol, 26, 269, 10.1016/j.beha.2013.10.007 Pizzitola, 2014, Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo, Leukemia, 28, 1596, 10.1038/leu.2014.62 2013, The Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia, N Engl J Med, 368, 2059, 10.1056/NEJMoa1301689 Welch, 2012, The origin and evolution of mutations in acute myeloid leukemia, Cell, 150, 264, 10.1016/j.cell.2012.06.023 Klco, 2014, Functional heterogeneity of genetically defined subclones in acute myeloid leukemia, Cancer Cell, 25, 379, 10.1016/j.ccr.2014.01.031 Duque-Afonso, 2014, The AML salad bowl, Cancer Cell, 25, 265, 10.1016/j.ccr.2014.03.002 Kronke, 2013, Clonal evolution in relapsed NPM1 mutated acute myeloid leukemia, Blood, 122, 100, 10.1182/blood-2013-01-479188 Markstein, 2013, Modeling colorectal cancer as a 3-dimensional disease in a dish: the case for drug screening using organoids, zebrafish, and fruit flies, Drug Discov Today Technol, 10, e73, 10.1016/j.ddtec.2012.12.005 Walsh, 2014, Quantitative optical imaging of primary tumor organoid metabolism predicts drug response in breast cancer, Cancer Res, 74, 5184, 10.1158/0008-5472.CAN-14-0663 Estey, 2013, Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia, Leukemia, 27, 1803, 10.1038/leu.2013.173 Jabbour, 2014, Potential mechanisms of disease progression and management of advanced-phase chronic myeloid leukemia, Leuk Lymphoma, 55, 1451, 10.3109/10428194.2013.845883 Sawyers, 2002, Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study, Blood, 99, 3530, 10.1182/blood.V99.10.3530 Giles, 2012, Nilotinib is effective in imatinib-resistant or intolerant patients with chronic myeloid leukemia in blastic phase, Leukemia, 26, 959, 10.1038/leu.2011.355 Cortes, 2008, Efficacy and safety of dasatinib in imatinib resistant or intolerant patients with chronic myeloid leukemia in blast phase, Leukemia, 22, 2176, 10.1038/leu.2008.221 Jiang, 2014, Allogeneic hematopoietic SCT in combination with tyrosine kinase inhibitor treatment compared with TKI treatment alone in CML blast crisis, Bone Marrow Transplant, 49, 1146, 10.1038/bmt.2014.146 Appelbaum, 2006, Age and acute myeloid leukemia, Blood, 107, 3481, 10.1182/blood-2005-09-3724 Yanada, 2008, Relapse and death during first remission in acute myeloid leukemia, Haematologica, 93, 633, 10.3324/haematol.12366 Thall, 2010, Bayesian models and decision algorithms for complex early phase clinical trials, Stat Sci, 25, 227, 10.1214/09-STS315 Rogatko, 2005, New paradigm in dose-finding trials: patient-specific dosing and beyond phase I, Clin Cancer Res, 11, 5342, 10.1158/1078-0432.CCR-05-0458 Galanis, 2014, Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants, Blood, 123, 94, 10.1182/blood-2013-10-529313 Estey, 2014, Acute myeloid leukemia: 2014 update on risk-stratification and management, Am J Hematol, 89, 1063, 10.1002/ajh.23834 Gyurkocza, 2010, Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia, J Clin Oncol, 28, 2859, 10.1200/JCO.2009.27.1460 Chen, 2015, The relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia, J Clin Oncol, 33, 1258, 10.1200/JCO.2014.58.3518 Adnane, 2006, Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature, Methods Enzymol, 407, 597, 10.1016/S0076-6879(05)07047-3 Röllig, 2014, Sorafenib versus placebo in addition to standard therapy in younger patients with newly diagnosed acute myeloid leukemia: results from 267 patients treated in the randomized placebo-controlled SAL-Soraml trial, Blood, 124, 6, 10.1182/blood.V124.21.6.6 Cortes, 2012, Final results of a phase 2 open-label, monotherapy efficacy and safety study of quizartinib (AC220) in patients ≥60 years of age with FLT3 ITD positive or negative relapsed/refractory acute myeloid leukemia, Blood, 120, 48, 10.1182/blood.V120.21.48.48 Marcucci, 2014, Adding KIT inhibitor dasatinib (DAS) to chemotherapy overcomes the negative impact of KIT mutation/over-expression in core binding factor (CBF) acute myeloid leukemia (AML): results from CALGB 10801 (Alliance), Blood, 124, 8, 10.1182/blood.V124.21.8.8 Social Security Administration. Retirement & survivors benefits: life expectancy calculator. Accessed at www.http://ssa.gov/oact/population Estey, 2003, New designs for phase 2 trials, Blood, 102, 442, 10.1182/blood-2002-09-2937 Hills, 2011, Applicability of a “pick a winner” trial design to acute myeloid leukemia, Blood, 118, 2389, 10.1182/blood-2011-02-337261 Petersdorf, 2013, A phase III study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia, Blood, 121, 10.1182/blood-2013-01-466706 Hills, 2014, Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials, Lancet Oncol, 15, 986, 10.1016/S1470-2045(14)70281-5 Ravandi, 2012, Gemtuzumab ozgamicin: time to resurrect?, J Clin Oncol, 30, 3921, 10.1200/JCO.2012.43.0132 Luskin, 2014, Results of the ECOG E1900 trial in younger adults with AML using an event free survival endpoint are concordant with results based on overall survival: potential for a surrogate endpoint to facilitate rapid approval of therapies in AML, Blood, 124, 2599, 10.1182/blood.V124.21.2599.2599